Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant's Ancure

This article was originally published in The Gray Sheet

Executive Summary

FDA is permitting implants of the abdominal aortic aneurysm stent graft on a "compassionate use" basis while the company conducts a recall of the product from hospitals, Guidant reports following a March 23 meeting with FDA. Problems related to the deployment of the minimally invasive system led to a March 16 announcement that the company would stop production and sales of the device (1"The Gray Sheet" March 19, 2001, In Brief) and take a $12-15 mil. charge to first-quarter earnings. Discussions with FDA are ongoing, Guidant says

You may also be interested in...



Guidant 's Ancure

Abdominal aortic anuerysm endovascular graft is recalled from existing hospital inventories and production halted by the company due to deficiencies in regulatory processes associated with deployment of the device and communications with the FDA, company reports March 16. The recall leaves Medtronic's AneuRx as the only AAA stent graft currently available on the U.S. market. Both firms have encountered problems in the past related to deployment of AAA devices. In November 1999, Guidant conducted a Class II recall of 287 Ancure units after a failure in the manufactuing process caused problems in the deployment of the product's attachment system

Celltrion Makes Progress On Coronavirus Treatment

Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.

Spain Lists Certain OTCs As 'Essential' In Fight Against COVID-19

Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.

UsernamePublicRestriction

Register

MT014680

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel